Loading
PDBj
メニューPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

7Q11

Crystal structure of CTX-M-14 in complex with Ixazomib

7Q11 の概要
エントリーDOI10.2210/pdb7q11/pdb
関連するPDBエントリー7Q0Y 7Q0Z
分子名称Beta-lactamase, DIMETHYL SULFOXIDE, [(1~{R})-1-[2-[[2,5-bis(chloranyl)phenyl]carbonylamino]ethanoylamino]-3-methyl-butyl]boronic acid, ... (6 entities in total)
機能のキーワードlactamase, antibiotic, resistence, hydrolase
由来する生物種Klebsiella pneumoniae
タンパク質・核酸の鎖数1
化学式量合計29173.76
構造登録者
Werner, N.,Perbandt, M.,Hinrichs, W.,Prester, A.,Rohde, H.,Aepfelbacher, M.,Betzel, C. (登録日: 2021-10-17, 公開日: 2022-04-13, 最終更新日: 2024-11-06)
主引用文献Perbandt, M.,Werner, N.,Prester, A.,Rohde, H.,Aepfelbacher, M.,Hinrichs, W.,Betzel, C.
Structural basis to repurpose boron-based proteasome inhibitors Bortezomib and Ixazomib as beta-lactamase inhibitors.
Sci Rep, 12:5510-5510, 2022
Cited by
PubMed Abstract: β-lactamases are a major cause of rapidly emerging and spreading antibiotic resistance. Currently β-lactamase inhibitors (BLIs) in clinical use act only on Ambler Class A, C and some class D lactamases. The urgent need to identify new BLIs recently lead to FDA approval of boron-based compounds BLIs, e.g. Vaborbactam. The boron-based proteasome inhibitors Bortezomib and Ixazomib are used in cancer therapy as multiple myeloma drugs but they also bind to Ser-/Thr- proteases. In this study we show the crystal structures of the β-lactamase CTX-M-14 with covalently bound Bortezomib and Ixazomib at high resolutions of 1.3 and 1.1 Å, respectively. Ixazomib is well defined in electron density whereas Bortezomib show some disorder which corresponds to weaker inhibition efficiency observed for Ixazomib. Both inhibitors mimic the deacylation transition state of β-lactam hydrolysis, because they replace the deacylating water molecule. We further investigate differences in binding of Bortezomib/Ixazomib to CTX-M-14 and its target proteases as well as known β-lactamase drugs. Our findings can help to use Bortezomib/Ixazomib as lead compounds for development of new BLIs.
PubMed: 35365689
DOI: 10.1038/s41598-022-09392-6
主引用文献が同じPDBエントリー
実験手法
X-RAY DIFFRACTION (1.14 Å)
構造検証レポート
Validation report summary of 7q11
検証レポート(詳細版)ダウンロードをダウンロード

239492

件を2025-07-30に公開中

PDB statisticsPDBj update infoContact PDBjnumon